Antithyroid drugs


Study Exclusion reasons Rmk Reference
Van Dijke, 1987 inadequate or absent control group EXCLUDED: only exposed group.

Van Dijke Ann Intern Med. 1987;106(1):60-61.

Uenaka, 2014 inadequate or absent control group EXCLUDED: no relevant control group.

Uenaka Eur. J. Obstet. Gynecol. Reprod. Biol. 2014; 177:89-93 10.1016/j.ejogrb.2014.03.007

Hawken (only exposed groups), 2016 inadequate or absent control group EXCLUDED: authors provided data on malformations only for Carbimazole exposed group and propylthiouracil exposed group. Therefore if we add these 2 groups to constitue a group 'antithyroid', there will not be a control group.

Hawken Ann. Endocrinol. (Paris) 2016; 77:570-577 10.1016/j.ando.2016.03.003

Nakagawa, 2002 inadequate or absent control group EXCLUDED: the 2 groups were treated during the beginning of pregnancy (group2: ATDs were withdrawn at 5·3 ± 0·5 (mean ± SE) months gestation). Apparent neonatal hypothyroidism and malformations were not observed in the offspring of either group.

Nakagawa Clin. Endocrinol. (Oxf) 2002; 57:467-71 10.1046/j.1365-2265.2002.01615.x

Lim (all treated with MMI), 1989 inadequate or absent control group EXCLUDED: all patient groups were treated with carbimazole.

Lim Singapore Med J 1989; 30:539-41

Dwarakanath (MMI versus PTU), 1999 inadequate or absent control group EXCLUDED: All patients treated (MMI only ; PTU only)

Dwarakanath Singapore Med J 1999; 40:70-3

Nachum, 2003 inadequate or absent control group

Nachum Am. J. Obstet. Gynecol. 2003; 189:159-65 10.1067/mob.2003.321

Pinheiro, 2008 inadequate or absent control group EXCLUDED: no analysis according to exposure to PTU versus no PTU.

Pinheiro Rev Bras Ginecol Obstet 2008; 30:452-8

Rodríguez, 2014 inadequate or absent control group EXCLUDED: number of cases exposed to MMI was reported (7/49), but there no control group (without malformations). In 7 patients (14.3%) Choanal Atresia was associated to prenatal exposure to maternal hyperthyroidism treated with methimazole.

Rodríguez Acta Otorrinolaringol Esp. 2014;65(2):85-92.

Vermes, 2016 not relevant exposure EXCLUDED: no exposure to ATD.

Vermes Congenit Anom (Kyoto) 2016; 56:65-72 10.1111/cga.12134

Luewan, 2011 not relevant exposure

Luewan Arch. Gynecol. Obstet. 2011; 283:243-7 10.1007/s00404-010-1362-z

Elston, 2014 not relevant exposure

Elston Aust N Z J Obstet Gynaecol 2014; 54:317-21 10.1111/ajo.12196

Doherty, 1995 not relevant exposure EXCLUDED: study not related to antithyroid drugs but on chirurgical management of thyroid cancer.

Doherty Laryngoscope 1995; 105:251-5 10.1288/00005537-199503000-00006

Abeillon-du-Payrat, 2014 not relevant study design EXCLUDED: study on the impact of the illness on neonatal thyroid status, with some details on ATD during pregnancy, but not sufficient to distinguish 2 groups (treated and untreated) and their outcomes.

Abeillon-du Payrat Eur. J. Endocrinol. 2014; 171:451-60 10.1530/EJE-14-0254

Burrow (PTU only), 1978 not relevant outcome 28 expo: 23 at least T1; 3 T1 only ; 1 T2 only ; 1 unknown. EXCLUDED: IQ provided as continuous variable or as deviation of normal values (but only on figures). Control group: Sibling children (considered as matched group)

Burrow The Yale journal of biology and medicine. 1978;51:151-156.

Messer, 1990 not relevant outcome EXCLUDED: continuous variable. CMZ: 16 pregnancies; PTU: 1 pregnancy.

Messer Acta Endocrinol. 1990; 123:311-6 10.1530/acta.0.1230311

Eisenstein, 1992 not relevant outcome EXCLUDED: continuous variable.

Eisenstein Eur. J. Pediatr. 1992; 151:558-9 10.1007/bf01957719

Lao, 1991 not relevant outcome EXCLUDED: Gestational age at delivery and Birth weight studied as continuous variables (5 birth weight below the 10th percentile were reported, but we did not know from which group they were).

Lao Gynecol. Obstet. Invest. 1991; 32:78-80 10.1159/000292999

Yang, 2013 data not abstractable EXCLUDED: for comparison with healthy control group: data only provided in the figure 1.

Yang J. Pediatr. Endocrinol. Metab. 2013; 26:1035-40 10.1515/jpem-2013-0107

Andersen 2013 (control unexposed, disease free), 2013 repeat population groups, duplicate reports (most recent study included) EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2013 based on a longer period and including more participants.

Andersen J. Clin. Endocrinol. Metab. 2013; 98:4373-81 10.1210/jc.2013-2831

Browne, 2009 repeat population groups, duplicate reports (most recent study included) EXCLUDED: Howley 2017 updated the study of Brown 2009. Data of Brown 2009 is included in Howley 2017 conducted on the same database with a longer study period: (1997-2011) for and (1997-2004) for Brown 2009.

Browne Birth Defects Res. Part A Clin. Mol. Teratol. 2009; 85:621-8 10.1002/bdra.20573

Andersen 2013 (control unexposed, sick), 2013 repeat population groups, duplicate reports (most recent study included) EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2013 based on a longer period and including more participants.

Andersen J. Clin. Endocrinol. Metab. 2013; 98:4373-81 10.1210/jc.2013-2831

Andersen 2014 (control unexposed, sick), 2014 repeat population groups, duplicate reports (most recent study included) EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2014 based on a longer period and including more participants.

Andersen Thyroid 2014; 24:1533-40 10.1089/thy.2014.0150

Andersen 2014 (control unexposed, disease free), 2014 repeat population groups, duplicate reports (most recent study included) EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2014 based on a longer period and including more participants.

Andersen Thyroid 2014; 24:1533-40 10.1089/thy.2014.0150

Yoshihara, 2015 repeat population groups, duplicate reports (most recent study included) EXCLUDED: Yoshihara 2012 used the same dataset on a smaller period (1999-2010) than Yoshihara 2015 (2000 - 2013) but with a higher number of exposed pregnancies (1426 MMI and 1578 PTU in 2012' study ; 1333 MMI in 2015' study).

Yoshihara Thyroid 2015; 25:1155-61 10.1089/thy.2014.0581

Andersen 2016, 2016 repeat population groups, duplicate reports (most recent study included) Exposure MMI/CMZ and/or PTU. In 2115 pregnancies, the mother redeemed prescriptions of ATDs (MMI/CMZ, n =1347; PTU, n = 1103, including a group of pregnancies with usage of both MMI/CMZ and PTU [n = 335]).

Andersen J. Clin. Endocrinol. Metab. 2016; 101:1606-14 10.1210/jc.2015-4274

Yoshihara, 2014 same data already obtained by other studies EXCLUDED: study conducted by the same authors, in the same hospital and during an overlapping period that the data published by Yoshihara et al. 2012 and Yoshihara et al. 2015, but with less exposed pregnancies.

Yoshihara J Thyroid Res 2014; 2014:952352 10.1155/2014/952352

Mintziori, 2012 article unavailable EXCLUDED: article unavailable.

Mintziori Minerva Med. 2012; 103:47-62

Lian, 2005 article unavailable EXCLUDED: article unavailable.

Lian Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005; 27:756-60

Vojvodic, 1990 article unavailable EXCLUDED: publication unavailable (in croatian).

Vojvodic Jugosl Ginekol Perinatol.1990 Sep-Dec;30(5-6):127-31.

Bakker, 2007 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: 'Thyroid therapy (H03)' analyzed as a whole, without distinction between thyroxine and antithyroid drugs.

Bakker Birth Defects Res. Part A Clin. Mol. Teratol. 2007; 79:652-6 10.1002/bdra.20388

Luton, 2005 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: study related to pregnant women TRAK and/or ATD, without specific analysis for ATD group (and no sufficient details in article).

Luton J. Clin. Endocrinol. Metab. 2005; 90:6093-8 10.1210/jc.2004-2555

Dorangeon, 1989 Studies without separate analysis of the considered drug/class from other drugs/class

Dorangeon Rev Fr Gynecol Obstet 1989; 84:905-13

Negro, 2010 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: no data on the antithyroid treatment.

Negro J. Clin. Endocrinol. Metab. 2010; 95:1699-707 10.1210/jc.2009-2009

Kallen, 2013 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: analysis performed on thyroid drugs (mainly thyroxin), without distinction between antithyroid drugs and thyroxin.

Kallen Pediatr Allergy Immunol 2013; 24:28-32 10.1111/pai.12034

Shahid, 2003 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: Analysis not performed according to exposure to carbimazole. Provided data did not allow to allocate fetal/neonatal outcomes according to exposure (carbimazole exposure are reported in the 2 groups).

Shahid J Coll Physicians Surg Pak 2003; 13:255-9 05.2003/JCPSP.255259

Guan, 2016 Studies without separate analysis of the considered drug/class from other drugs/class 7 patients were subclinically hyperthyroid after iodine-131 treatment, and their administered PTU doses were 25 ± 12.5 mg/d.

Guan Biosci Trends 2016; 10:307-14 10.5582/bst.2016.01008

Van Veenendaal, 2016 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: Case-control: analyses performed on Subgroups of Medication. An other investigation is performed: the malformations reported in pregnant women exposed to PTU, but there is no control group.

van Veenendaal Birth Defects Res. Part A Clin. Mol. Teratol. 2016; 106:573-9 10.1002/bdra.23497

Harborne, 2005 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: outcomes of pregnancy were not detailed for women with Hyperthyroidism treated with Carbimazole or Propylthiouracil. The study described therapeutic intervention throughout pregnancy and outcomes (but not according to exposure).

Harborne Aust N Z J Obstet Gynaecol 2005; 45:239-42 10.1111/j.1479-828X.2005.00365.x

Musselman, 2013 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: results provided for 'thyroid medication use', without other details (antithyroid or thyroid hormones ???)

Musselman Cancer Epidemiol 2013; 37:318-20 10.1016/j.canep.2012.12.005

Nambiar, 2011 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: study on the effect of thyroid dysfunction on pregnancy outcome, without analysis according to the use of antithyroid drugs or not.

Nambiar J Thyroid Res 2011; 2011:429097 10.4061/2011/429097

Bakker, 2006 pattern of exposure EXCLUDED: only on prescription patterns, without data of fetal/neonatal outcomes.

Bakker BJOG 2006; 113:559-68 10.1111/j.1471-0528.2006.00927.x